Bullous Pemphigoid (BP) Clinical Trials and Treatments

Bullous pemphigoid (BP) is an autoimmune blistering disorder characterized by formation of large, tense blisters on an erythematous or urticarial base due to autoimmune attack on basement membrane proteins. The disease is caused by IgG autoantibodies against hemidesmosomal proteins, particularly BP180 (type XVII collagen, 180-kilodalton ectodomain) and BP230 (bullous pemphigoid antigen 1, 230 kDa), which are structural components of hemidesmosomes anchoring basal keratinocytes to the basement membrane. These autoantibodies bind to the basement membrane zone, trigger complement activation, and recruit inflammatory cells including neutrophils and eosinophils, leading to subepidermal blister formation with characteristic preservation of the basal cell layer (unlike pemphigus where blisters form intraepidermally).

The most common symptoms of Bullous Pemphigoid include Large tense blisters on flexural skin, Urticarial or eczematous plaques, Intense pruritus, Erosions and crusting, Oral mucosal involvement, among others. Approximately 2-23 per million people per year; incidence increases sharply with age. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Bullous Pemphigoid from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials are actively evaluating immunosuppressive agents, complement inhibitors, and targeted biologic therapies for bullous pemphigoid to improve outcomes and reduce corticosteroid dependence. B-cell targeting therapies and agents blocking specific inflammatory pathways show promise for steroid-sparing approaches that reduce long-term corticosteroid complications.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Bullous Pemphigoid. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

The exact cause of Bullous Pemphigoid is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune (antibodies to BP180 and BP230 hemidesmosome proteins); no gene test. Approximately 2-23 per million people per year; incidence increases sharply with age. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Bullous Pemphigoid. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune (antibodies to BP180 and BP230 hemidesmosome proteins); no gene test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Bullous Pemphigoid clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Bullous Pemphigoid clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.